OTTAWA, Dec. 19 /CNW/ -- ZLB Behring today announced that Health Canada has granted the company authorization to market Sandoglobulin(R) NF Liquid throughout Canada. Marketing will be accomplished by ZLB Behring Canada, Inc.
Sandoglobulin(R) NF Liquid (Immune Globulin (Human)), which is administered intravenously, is indicated for the treatment of adult and pediatric patients who have conditions known as primary immune deficiency (PI) or secondary
immune deficiency (SI), both of which are rare and life- threatening. Authorization was granted on November 3, 2006.
